GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides - Test2 - elhamkhani - TriplyDB

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

http://www.wikidata.org/entity/Q28205921

about

sameAs

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS Pro-inflammatory interleukin-18 increases Alzheimer's disease-associated amyloid-β production in human neuron-like cells Insulin in central nervous system: more than just a peripheral hormone PAR-4 is involved in regulation of beta-secretase cleavage of the Alzheimer amyloid precursor protein Interactome mapping of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway identifies deformed epidermal autoregulatory factor-1 as a new glycogen synthase kinase-3 interactor GSK-3 phosphorylates delta-catenin and negatively regulates its stability via ubiquitination/proteosome-mediated proteolysis Glycogen synthase kinase 3: more than a namesake Regulation of glycogen synthase kinase-3 during bipolar mania treatment Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder Neuronal regeneration in a zebrafish model of adult brain injury The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis Metabolic syndrome and the role of dietary lifestyles in Alzheimer's disease Alzheimer's disease; taking the edge off with cannabinoids?Gleevec inhibits beta-amyloid production but not Notch cleavage Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics Lithium facilitates apoptotic signaling induced by activation of the Fas death domain-containing receptor A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts The Rationale for Insulin Therapy in Alzheimer's Disease The roles of lipid and glucose metabolism in modulation of β-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets Diabetes and Alzheimer disease, two overlapping pathologies with the same background: oxidative stress Aberrant insulin signaling in Alzheimer's disease: current knowledge Intraneuronal Aβ accumulation induces hippocampal neuron hyperexcitability through A-type K(+) current inhibition mediated by activation of caspases and GSK-3.Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418 Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma Targeting neuroinflammation in Alzheimer's disease Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease The ups and downs of Wnt signaling in prevalent neurological disorders Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model.Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice A functional mouse retroposed gene Rps23r1 reduces Alzheimer's beta-amyloid levels and tau phosphorylation Degradative organelles containing mislocalized alpha-and beta-synuclein proliferate in presenilin-1 null neurons Regulation of Alzheimer's disease amyloid-beta formation by casein kinase I NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations

P2860

2a8f76e648bfa3f0172141af5f5c1e97f820c2c9 f70df3f4dbe7993e682df4986d4526c7867d30e6

P248

Q21129334-097DF0FD-B467-4689-93C0-4A783D3793A7 Q21245229-2BC6FC86-D774-4B05-9893-6B4902F4C33B Q21296648-8668F838-27BF-4287-9BA3-6E76D4D5211D Q24292718-6065E73A-D78D-49FF-92A6-F71A32BEA15C Q24305619-C28D5E5E-F10F-4402-A801-A57EA8669550 Q24309369-26F3A900-A8AD-4A73-BF48-2E40E79E770C Q24315635-B19660F9-96E2-4495-AC3B-4812BC497A44 Q24594534-3230810A-E965-41CD-9E06-5FBD73F376A9 Q24626017-801D30AB-593D-46D1-AF7A-0A5032E59755 Q24627519-905F398C-FF16-469C-B694-55621F1F259C Q24651407-5F3234BD-6899-43B6-8EB7-E2F552EBBABD Q24654247-8ACEAC39-9CBE-418E-94D9-AB784ACF1E77 Q24681412-56F2ADD6-8BD7-49FB-AF8F-9225A661DE7B Q24683037-12F98F6E-CE39-40D0-BC57-258354C76ECF Q24685475-E8E6991D-69B1-4E20-BEB3-E043C4E93929 Q24791054-B79B2878-97C5-4D27-8424-16AF3523D950 Q26741164-3D5096EF-11D7-416B-ABFF-76C4A3F03927 Q26744834-49382824-78D1-4A08-B89C-043931BD5009 Q26777969-473CB6D1-7289-438E-AFE9-240FF813A45C Q26783344-8FF18BF3-8448-4AAC-A638-4E94F3987395 Q26860246-69E9D9B9-D978-4FC1-93FF-35E193C96EA7 Q26865654-17B3FB84-AF69-4CDF-82A5-8ACE7971092D Q27022552-88343733-46FC-4A3A-AC79-FEAF1649007C Q27024222-3785BDE4-4218-48FE-B5BD-51897B8DDAB2 Q27307787-E6351877-F510-40A2-A531-51DAF519A83E Q27641873-69972B71-5EDC-42F6-9FC3-355DCF5B8913 Q28075617-6E4B4B68-BD35-4322-9E46-DFF91BD0D98B Q28078474-80825D03-4C37-43C1-8D8F-FDF8E2C3B4BC Q28251880-6757A3F2-21F2-47E7-986D-B1A1791F7A05 Q28259585-2A4BC18D-CD4E-4805-AD98-8366F84254D3 Q28277009-148B956E-3E30-4A2F-B7DA-203E6B1796DE Q28394506-4B2E8099-9F88-49D4-A9CF-86E5832201DA Q28468536-0945CB43-4842-4EEB-8EDB-80A2F5F89ECA Q28469220-21D7D595-556A-4B88-A23E-28B330F7C6A7 Q28476571-86AD7165-9D35-498C-BB01-C980564F0046 Q28507501-28F7B773-A69B-42B5-9087-0CBED39761F7 Q28511388-AFF73F8E-7A09-4AD0-B1EE-7B577C75ADF2 Q28577875-906DAD7B-B0BC-45E2-891A-D48F67D10924 Q28586033-6B2FEE80-2542-4F8B-81FA-A0C497BA7D40 Q28587440-02930F5E-657B-4A77-979F-16C3E938804D

P2860

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

http://www.wikidata.org/entity/Q28205921

description

2003 nî lūn-bûn

@nan

2003 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

@ast

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

@en

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

@nl

type

label

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

@ast

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

@en

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

@nl

prefLabel

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

@ast

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

@en

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

@nl

P1433

Q28205921-400EC1B2-96F6-4B92-B0FC-EF7DE870A9AC

P1476

Q28205921-47A06228-1C0F-4EE0-829D-93E96F16F939

P2093

Q28205921-28EDEFFA-ECB2-432B-A7E1-F1CB4E2FFB8E

Q28205921-38C7E4D3-A097-4740-BB49-1CFC99AB18FA

Q28205921-54271E73-F931-46B2-A029-A28A887F96E7

Q28205921-C7F5A43B-6892-4B76-871E-A568B74EBCAE

P2860

Q28205921-008527A5-5C1B-483C-8092-9F333DB55A9B

Q28205921-0CD54AD5-78FC-458E-B7CC-A0D17716D6C5

Q28205921-2063A3AA-C98C-4C82-B081-8FA919602192

Q28205921-3B2E4507-0D59-44B9-9AF3-28043975BFF2

Q28205921-40B5B405-DC84-4178-8F49-A10A99FD4A0D

Q28205921-4F4A863A-48F5-4E2C-AE4E-FB12A6A62367

Q28205921-547FF2B6-EA7E-425E-8639-2D0C225E6F43

Q28205921-A37AA3F2-ABB2-4332-A1CB-79D91FF539B2

Q28205921-CE18C960-CC26-4EF6-B0AC-B462B2A5998F

Q28205921-E4B782BA-29D4-479E-994A-2EA8C3F39429

P2888

Q28205921-BEADA70C-C523-4AAF-824A-14F51987D496

P304

Q28205921-6A56B493-58AC-49A6-AD0C-1925CBA8705A

P31

Q28205921-EA33A641-686F-4CDE-BD78-593CEA66B4B9

P3181

Q28205921-C569CC07-D83B-4A2D-A036-6FB2C0FD2BE1

P356

Q28205921-A4DCABEC-8825-4042-8340-44CBF02D53D5

P407

Q28205921-16A327B7-37E1-4992-AB6A-25382A10CF74

P433

Q28205921-F11E6CC1-75F9-49D2-9C4E-B7A69DBCD633

P478

Q28205921-E53E73B4-28A2-4B01-A49D-B1532EF7A583

P577

Q28205921-2E807159-A4E6-46F5-9EDC-C7F36221CBF3

P5875

Q28205921-C5DB0467-3D1E-4C21-B2CE-D8A317EE7324

P6179

Q28205921-EEC26718-BCF4-4128-969E-7F231BD5D11D

P698

Q28205921-29BC8AF0-5CE7-454E-B861-2F35FCEAF10B

P921

Q28205921-2F87270E-7C7D-4BD7-8E0B-FE19565E667C

Q28205921-BDEB5DE3-4EEB-4FF6-AAFD-7BB0C4B25AF7

Q28205921-FDFDFC70-8ABB-4D58-AA35-A7CE43EB0BEB

P3181

P356

P1433

P1476

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

@en

P2093

Christina A Wilson

http://www.w3.org/2001/XMLSchema#string

Christopher J Phiel

http://www.w3.org/2001/XMLSchema#string

Peter S Klein

http://www.w3.org/2001/XMLSchema#string

Virginia M-Y Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing

Substitution of a glycogen synthase kinase-3beta phosphorylation site in presenilin 1 separates presenilin function from beta-catenin signaling

Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau

A molecular mechanism for the effect of lithium on development

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation

A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain

Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein

Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain

P2888

P304

435-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2680420

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NATURE01640

http://www.w3.org/2001/XMLSchema#string

P407

P433

6938

http://www.w3.org/2001/XMLSchema#string

P478

423

http://www.w3.org/2001/XMLSchema#string

P577

2003-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232800767

http://www.w3.org/2001/XMLSchema#string

P6179

1008545424

http://www.w3.org/2001/XMLSchema#string

P698

12761548

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

positive regulation of amyloid-beta formation

Glycogen synthase kinase 3 alpha